Future perspectives on engineered T cells for cancer.

Area of Science:

• Immunology and Cancer Therapy
• Cellular Therapy for Solid Tumors

Background:

• Chimeric antigen receptor (CAR) T cell therapy is a breakthrough for blood cancers but faces significant hurdles in solid tumors.
• The solid tumor microenvironment (TME) causes T cell dysfunction, exhaustion, and reduced anti-tumor activity, mimicking tumor-infiltrating lymphocytes (TILs).

Purpose of the Study:

• To review recent advancements in CAR T cell therapy for solid tumors, with a focus on brain cancers.
• To discuss challenges and innovative strategies to enhance CAR T cell efficacy and safety in the TME.

Main Methods:

• Review of current literature on CAR T cell therapy for solid tumors.
• Analysis of strategies to overcome T cell dysfunction and improve CAR T cell persistence.
• Discussion of toxicity management and emerging therapeutic approaches.

Main Results:

• CAR T cell therapy efficacy is limited in solid tumors due to TME-induced T cell exhaustion and dysfunction.
• Innovative strategies like locoregional delivery and cytokine 'armoring' (e.g., IL-18) are being explored.
• Toxicity management remains a critical aspect of CAR T cell therapy development.

Conclusions:

• Overcoming T cell exhaustion and the hostile TME are key to successful CAR T cell therapy for solid tumors.
• Novel strategies are essential for improving CAR T cell function, safety, and clinical application in brain cancers and other solid malignancies.
• Continued research into combination therapies and toxicity mitigation is crucial for advancing this treatment modality.